Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: breathing difficulties; wheezy breathing; Death; This is a spontaneous report from a contactable physician downloaded from the Medicines Agency (MA) Regulatory Authority-WEB, Regulatory Authority number SE-MPA-2021-002698. Other case identifier number SE-MPA-1612445101419. A 77-year-old male patient received second dose of bnt162b2 (COMIRNATY, lot/batch number unknown), intramuscular in Feb2021 at 0.3 mL, single for covid-19 immunisation. Medical history included alzheimers disease, dementia, hypertension, aortic valve insufficiency, late effects of cerebral stroke. Patient received first dose of bnt162b2 (COMIRNATY) on 12Jan2021 for covid-19 immunisation. Concomitant medications were Alvedon, Duroferon, Furix, Haldol, Heminevrin, Hiprex, Miniderm, Robinul, acetylsalicylic acid, buprenorphine, folic acid, memantine, metoprolol, midazolam, mirtazapine, morphine, zopiclone. The reporter wrote "Patient had breathing difficulties with wheezy breathing...". The patient died within 24 hours after vaccination in Feb2021. Event reported as serious due to death. No autopsy performed. The outcome of events was fatal. Information on the lot/batch number has been requested.; Reported Cause(s) of Death: Death; breathing difficulties; wheezy breathing
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166